Plus Therapeutics is pleased to announce that the Company will present three new clinical data updates at this year’s World Federation of Neuro-Oncology Societies (WFNOS) / Society for Neuro-Oncology (SNO) Annual Meeting. The conference, one of the largest global gatherings in neuro-oncology, will take place this week and brings together leading clinicians, researchers, and industry innovators focused on improving outcomes for patients with central nervous system (CNS) tumors.
These upcoming presentations highlight the continued progress of Plus Therapeutics’ radiotherapeutic pipeline, including advancements in the Company’s clinical programs for leptomeningeal metastases (LM), glioblastoma (GBM), and other difficult-to-treat CNS cancers.
Visit Us at the SNO 2025 Exhibit Hall
If you are attending WFNOS/SNO, we invite you to visit both of our exhibit booths to learn more about the Company’s latest developments in CNS oncology:
-
Plus Therapeutics Booth #317
Explore the Company’s precision radiotherapeutic technologies, including updates on REYOBIQ™ and ongoing clinical trials such as ReSPECT-LM and ReSPECT-GBM.
Our scientific and clinical teams will be available to discuss emerging data, ongoing research collaborations, and upcoming milestones across our neuro-oncology programs.
Stay Connected
More information about our clinical programs, scientific presentations, and research collaborations will be shared as data becomes available.
Recent Comments